Clinical trial
A Prospective, Open-label, Randomized, Phase II Study of the Efficacy and Safety of Sintilimab Combined With Chemotherapy Versus Chemotherapy in Perioperative Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma (ECTOP-2006).
NCT06152978 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open-label, Randomized, Phase II Study of the Efficacy and Safety of Sintilimab Combined With Chemotherapy Versus Chemotherapy in Perioperative Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma (ECTOP-2006).
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 15, 2023
- Completion date
- December 15, 2027
- Enrollment
- 182 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.